skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 5,443  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
Material Type:
Article
Add to My Research

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Eye (London), 2013-07, Vol.27 (7), p.787-794 [Peer Reviewed Journal]

Copyright Nature Publishing Group Jul 2013 ;Copyright © 2013 Royal College of Ophthalmologists 2013 Royal College of Ophthalmologists ;ISSN: 0950-222X ;EISSN: 1476-5454 ;DOI: 10.1038/eye.2013.107 ;PMID: 23722722

Full text available

2
Ocular Drug Delivery: Present Innovations and Future Challenges
Material Type:
Article
Add to My Research

Ocular Drug Delivery: Present Innovations and Future Challenges

The Journal of pharmacology and experimental therapeutics, 2019-09, Vol.370 (3), p.602 [Peer Reviewed Journal]

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics. ;EISSN: 1521-0103 ;DOI: 10.1124/jpet.119.256933 ;PMID: 31072813

Full text available

3
Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track
Material Type:
Article
Add to My Research

Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track

British journal of ophthalmology, 2012-08, Vol.96 (8), p.1084-1087 [Peer Reviewed Journal]

2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;2015 INIST-CNRS ;Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2011-301016 ;PMID: 22368262 ;CODEN: BJOPAL

Full text available

4
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
Material Type:
Article
Add to My Research

Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration

Cochrane database of systematic reviews, 2020-05, Vol.2020 (5), p.CD012208 [Peer Reviewed Journal]

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD012208.pub2 ;PMID: 32374423

Full text available

5
Intravitreal injections in the context of incarcerated patients
Material Type:
Article
Add to My Research

Intravitreal injections in the context of incarcerated patients

Probacja, 2023-11, Vol.4, p.337-347 [Peer Reviewed Journal]

ISSN: 1689-6122 ;EISSN: 2719-311X ;DOI: 10.5604/01.3001.0054.1341

Full text available

6
Application of intravitreal aflibercept to treat bilateral exudative retinal detachment secondary to retinitis pigmentosa: Case report and review of literature
Material Type:
Article
Add to My Research

Application of intravitreal aflibercept to treat bilateral exudative retinal detachment secondary to retinitis pigmentosa: Case report and review of literature

Medicine (Baltimore), 2023-12, Vol.102 (51), p.e36589-e36589 [Peer Reviewed Journal]

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. ;Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. 2023 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000036589 ;PMID: 38134121

Full text available

7
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Material Type:
Article
Add to My Research

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

The Lancet (British edition), 2022-02, Vol.399 (10326), p.729-740 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00010-1 ;PMID: 35085502

Full text available

8
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Material Type:
Article
Add to My Research

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

The Lancet (British edition), 2019-10, Vol.394 (10208), p.1551-1559 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)31344-3 ;PMID: 31522845

Full text available

9
Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy
Material Type:
Article
Add to My Research

Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy

Theranostics, 2023-01, Vol.13 (7), p.2241-2255 [Peer Reviewed Journal]

The author(s). ;The author(s) 2023 ;ISSN: 1838-7640 ;EISSN: 1838-7640 ;DOI: 10.7150/thno.78426 ;PMID: 37153730

Full text available

10
Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study
Material Type:
Article
Add to My Research

Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study

Graefe's archive for clinical and experimental ophthalmology, 2023-08, Vol.261 (8), p.2421-2429 [Peer Reviewed Journal]

The Author(s) 2023 ;ISSN: 0721-832X ;EISSN: 1435-702X ;DOI: 10.1007/s00417-023-05989-3

Digital Resources/Online E-Resources

11
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Material Type:
Article
Add to My Research

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

The Lancet (British edition), 2022-02, Vol.399 (10326), p.741-755 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00018-6 ;PMID: 35085503

Full text available

12
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study
Material Type:
Article
Add to My Research

Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study

American journal of ophthalmology, 2019-01, Vol.197, p.156-167 [Peer Reviewed Journal]

2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jan 2019 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2018.08.026 ;PMID: 30148987

Full text available

13
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Material Type:
Article
Add to My Research

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

British journal of ophthalmology, 2015-02, Vol.99 (2), p.220-226 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2014-305327 ;PMID: 25193672 ;CODEN: BJOPAL

Full text available

14
Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection
Material Type:
Article
Add to My Research

Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection

Journal of ocular pharmacology and therapeutics, 2023-04, Vol.39 (3), p.215-224 [Peer Reviewed Journal]

Marjorie A. Peraza et al. 2023; Published by Mary Ann Liebert, Inc. ;Marjorie A. Peraza et al. 2023; Published by Mary Ann Liebert, Inc. 2023 Marjorie A. Peraza et al. ;ISSN: 1080-7683 ;EISSN: 1557-7732 ;DOI: 10.1089/jop.2022.0059 ;PMID: 36880872

Full text available

15
Power of compounding intravitreal Bevacizumab - Experience from a tertiary eye care hospital
Material Type:
Article
Add to My Research

Power of compounding intravitreal Bevacizumab - Experience from a tertiary eye care hospital

Indian journal of ophthalmology, 2022-05, Vol.70 (5), p.1869-1869 [Peer Reviewed Journal]

COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd. ;2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Copyright: © 2022 Indian Journal of Ophthalmology 2022 ;ISSN: 0301-4738 ;EISSN: 1998-3689 ;DOI: 10.4103/ijo.IJO_1016_22 ;PMID: 35502117

Full text available

16
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Material Type:
Article
Add to My Research

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

The New England journal of medicine, 2015-03, Vol.372 (13), p.1193-1203 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;Copyright © 2015 Massachusetts Medical Society. 2015 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1414264 ;PMID: 25692915

Full text available

17
Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study
Material Type:
Article
Add to My Research

Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study

American journal of ophthalmology, 2015-07, Vol.160 (1), p.35-44.e1 [Peer Reviewed Journal]

Elsevier Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jul 2015 ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2015.04.021 ;PMID: 25896459 ;CODEN: AJOPAA

Full text available

18
Short-term efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-naïve exudate Age-related Macular Degeneration; A Multicenter Study
Material Type:
Article
Add to My Research

Short-term efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-naïve exudate Age-related Macular Degeneration; A Multicenter Study

Korean journal of ophthalmology, 2023-10, Vol.37 (5), p.365-372 [Peer Reviewed Journal]

2023 The Korean Ophthalmological Society 2023 ;ISSN: 1011-8942 ;EISSN: 2092-9382 ;DOI: 10.3341/kjo.2023.0009 ;PMID: 37562440

Full text available

19
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Material Type:
Article
Add to My Research

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Cochrane database of systematic reviews, 2014-08, Vol.8 (8), p.CD005139-CD005139 [Peer Reviewed Journal]

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2014 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD005139.pub3 ;PMID: 25170575

Full text available

20
Pharmacology of Corticosteroids for Diabetic Macular Edema
Material Type:
Article
Add to My Research

Pharmacology of Corticosteroids for Diabetic Macular Edema

Investigative ophthalmology & visual science, 2018-01, Vol.59 (1), p.1-12 [Peer Reviewed Journal]

Copyright 2018 The Authors 2018 ;ISSN: 1552-5783 ;ISSN: 0146-0404 ;EISSN: 1552-5783 ;DOI: 10.1167/iovs.17-22259 ;PMID: 29297055

Full text available

Results 1 - 20 of 5,443  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (5,149)

Refine My Results

Creation Date 

From To
  1. Before 1987  (9)
  2. 1987 To 1995  (21)
  3. 1996 To 2004  (41)
  4. 2005 To 2014  (1,771)
  5. After 2014  (3,589)
  6. More options open sub menu

Language 

  1. English  (5,115)
  2. Japanese  (663)
  3. French  (123)
  4. Portuguese  (93)
  5. Korean  (83)
  6. Spanish  (66)
  7. German  (60)
  8. Chinese  (46)
  9. Norwegian  (11)
  10. Russian  (10)
  11. Turkish  (9)
  12. Czech  (3)
  13. Swedish  (2)
  14. Polish  (1)
  15. Italian  (1)
  16. Persian  (1)
  17. Croatian  (1)
  18. More options open sub menu

Searching Remote Databases, Please Wait